Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 243 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Escitalopram Oxalate Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Emotional and Cognitive Control in Late-Onset Depression

NCT01728194
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
2
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Research Evaluating the Value of Augmenting Medication With Psychotherapy

NCT00057551
View directory record Official record
Conditions
Depression, Depressive Disorder
Interventions
Brief Supportive Psychotherapy, CBASP, Medication Only
Behavioral · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Tucson, Arizona • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Functional Dyspepsia Treatment Trial

NCT00248651
View directory record Official record
Conditions
Dyspepsia and Other Specified Disorders of Function of Stomach
Interventions
Amitriptyline, Escitalopram, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 7, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional Results available

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

NCT05289830
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Periampullary Cancer
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Anxiety and Depression in Epilepsy: A Treatment Study

NCT03464383
View directory record Official record
Conditions
Anxiety, Depression, Epilepsy
Interventions
Escitalopram 10mg, Referral to Psychiatry, Survey only
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Depression, Epinephrine, and Platelet Function

NCT00166114
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Desipramine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Not applicable Interventional Results available

Safety and Effectiveness of S-adenosyl-l-methionine (SAMe) for the Treatment of Major Depression

NCT00101452
View directory record Official record
Conditions
Depression
Interventions
S-adenosyl-l-methionine, Escitalopram, Placebo
Drug
Lead sponsor
Maurizio Fava, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cellular Aging and Neurobiology of Depression Study

NCT00285935
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Standard Clinical Care with an SSRI
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 60 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 7, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111552
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

NCT05536414
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Centanafadine, Escitalopram, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Yuma, Arizona • Bryant, Arkansas • Glendale, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 7, 2026, 10:55 AM EDT
Enrolling by invitation Phase 2 Interventional

Neuroimaging of Escitalopram in Autism Spectrum Disorder

NCT06826326
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Escitalopram 10mg, Placebo
Drug
Lead sponsor
Kathryn Unruh
Other
Eligibility
12 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Brain Imaging and Treatment Studies of the Night Eating Syndrome

NCT01401595
View directory record Official record
Conditions
Night Eating Syndrome
Interventions
escitalopram oxalate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

NCT00531622
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
saredutant (SR48968), escitalopram, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression

NCT00070694
View directory record Official record
Conditions
Depressive Disorder
Interventions
MDL100.907
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder

NCT00107120
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
28
States / cities
Sacramento, California • San Diego, California • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Depression-Diabetes Mechanisms: Urban African Americans

NCT00209170
View directory record Official record
Conditions
Diabetes, Depression
Interventions
Beating the Blues, Escitalopram, Placebo
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 81 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 7, 2026, 10:55 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity

NCT04221256
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Administration of SSRI escitalopram, Paired Associative stimulation, Administration of Placebo
Drug · Behavioral
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 4 Interventional

Escitalopram Treatment of Patients With Agitated Dementia

NCT00260624
View directory record Official record
Conditions
Alzheimer's Disease, Psychomotor Agitation
Interventions
Escitalopram (Lexapro)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
61 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Fairport, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stress and Inflammation in Late-Life Depression

NCT02389465
View directory record Official record
Conditions
Depression, Inflammation
Interventions
Escitalopram + Celecoxib, Escitalopram + Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 7, 2026, 10:55 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

NCT01944657
View directory record Official record
Conditions
1. Major Depressive Disorder
Interventions
Supplemental TMS, Standard Medication Monotherapy
Device · Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 7, 2026, 10:55 AM EDT
Not listed Phase 3 Interventional

Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

NCT00239954
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
Pharmacology Research Institute
Other
Eligibility
18 Years to 80 Years
Timeline
Started 2005
U.S. locations
4
States / cities
Los Alamitos, California • Newport Beach, California • Northridge, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 7, 2026, 10:55 AM EDT
Not listed Phase 1 Interventional

Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury (SCI)

NCT01753882
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Lexapro, Placebo
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

SSRI and Buprenorphine

NCT00475878
View directory record Official record
Conditions
Opiate Dependence, Depression
Interventions
escitalopram, placebo
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 7, 2026, 10:55 AM EDT
Completed Not applicable Interventional

Preventing Post-Stroke Depression

NCT00071643
View directory record Official record
Conditions
Depression, Cerebrovascular Accident
Interventions
Problem Solving Therapy, Escitalopram, Placebo
Behavioral · Drug · Other
Lead sponsor
Robert G. Robinson
Other
Eligibility
31 Years to 89 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 7, 2026, 10:55 AM EDT